• Je něco špatně v tomto záznamu ?

Inotropika u pacientů s onemocněním srdce - aktuální stav v roce 2011
[Inotropes in cardiac patients: Update 2011]

John T. Parissis, Pinelopi Rafouli-Stergiou, Vassilios Stasinos, Panagiotis Psarogiannakopoulos, Alexandre Mebazaa

Jazyk čeština Země Česko

Typ dokumentu přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc11011661

ICU patients frequently develop low output syndromes due to cardiac dysfunction, myocardial injury, and inflammatory activation. Conventional inotropic agents seem to be useful in restoring hemodynamic parameters and improving peripheral organ perfusion, but can increase short-term and long-term mortality in these patients. Novel inotropes may be promising in the management of ICU patients, having no serious adverse effects. This review summarizes all the current knowledge about the use of conventional and new inotropic agents in various clinical entities of critically ill patients. RECENT FINDINGS: In recent European Society of Cardiology guidelines, inotropic agents are administered in patients with low output syndrome due to impaired cardiac contractility, and signs and symptoms of congestion. The most recommended inotropes in this condition are levosimendan and dobutamine (both class of recommendation: IIa, level of evidence: B). Recent data indicate that levosimendan may be useful in postmyocardial infarction cardiac dysfunction and septic shock through increasing coronary flow and attenuating inflammatory activation, respectively. Furthermore, calcium sensitizing by levosimendan can be effectively used for weaning of mechanical ventilation in postcardiac surgery patients and has also cardioprotective effect as expressed by the absence of troponin release in this patient population. Finally, new agents, such as istaroxime and cardiac myosin activators may be safe and improve central hemodynamics in experimental models of heart failure and heart failure patients in phase II clinical trials; however, large-scale randomized clinical trials are required. SUMMARY: In an acute cardiac care setting, short-term use of inotropic agents is crucial for the restoration of arterial blood pressure and peripheral tissue perfusion, as well as weaning of cardiosurgery. New promising agents should be tested in randomized clinical trials.

Inotropes in cardiac patients: Update 2011

Bibliografie atd.

Lit.: 84

000      
00000naa 2200000 a 4500
001      
bmc11011661
003      
CZ-PrNML
005      
20111210211049.0
008      
110525s2011 xr e cze||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a cze $b eng
044    __
$a xr
100    1_
$a Parissis, John T.
245    10
$a Inotropika u pacientů s onemocněním srdce - aktuální stav v roce 2011 / $c John T. Parissis, Pinelopi Rafouli-Stergiou, Vassilios Stasinos, Panagiotis Psarogiannakopoulos, Alexandre Mebazaa
246    11
$a Inotropes in cardiac patients: Update 2011
314    __
$a Heart Failure Unit, Attikon University Hospital, Athens, Greece. jparissis@yahoo.com
504    __
$a Lit.: 84
520    9_
$a ICU patients frequently develop low output syndromes due to cardiac dysfunction, myocardial injury, and inflammatory activation. Conventional inotropic agents seem to be useful in restoring hemodynamic parameters and improving peripheral organ perfusion, but can increase short-term and long-term mortality in these patients. Novel inotropes may be promising in the management of ICU patients, having no serious adverse effects. This review summarizes all the current knowledge about the use of conventional and new inotropic agents in various clinical entities of critically ill patients. RECENT FINDINGS: In recent European Society of Cardiology guidelines, inotropic agents are administered in patients with low output syndrome due to impaired cardiac contractility, and signs and symptoms of congestion. The most recommended inotropes in this condition are levosimendan and dobutamine (both class of recommendation: IIa, level of evidence: B). Recent data indicate that levosimendan may be useful in postmyocardial infarction cardiac dysfunction and septic shock through increasing coronary flow and attenuating inflammatory activation, respectively. Furthermore, calcium sensitizing by levosimendan can be effectively used for weaning of mechanical ventilation in postcardiac surgery patients and has also cardioprotective effect as expressed by the absence of troponin release in this patient population. Finally, new agents, such as istaroxime and cardiac myosin activators may be safe and improve central hemodynamics in experimental models of heart failure and heart failure patients in phase II clinical trials; however, large-scale randomized clinical trials are required. SUMMARY: In an acute cardiac care setting, short-term use of inotropic agents is crucial for the restoration of arterial blood pressure and peripheral tissue perfusion, as well as weaning of cardiosurgery. New promising agents should be tested in randomized clinical trials.
650    _2
$a kardiotonika $x terapeutické užití $7 D002316
650    _2
$a kritický stav $x terapie $7 D016638
650    _2
$a lidé $7 D006801
655    _2
$a přehledy $7 D016454
700    1_
$a Rafouli-Stergiou, Pinelopi
700    1_
$a Stasinos, Vassilios
700    1_
$a Psarogiannakopoulos, Panagiotis
700    1_
$a Mebazaa, Alexandre
773    0_
$w MED00156011 $t Current opinion in critical care $g Roč. 5, č. 1 (2011), s. 15-24 $x 1802-3819
910    __
$a ABA008 $b B 2484 $c 422 $y 1
990    __
$a 20110525093044 $b ABA008
991    __
$a 20110525102612 $b ABA008
999    __
$a ok $b bmc $g 852785 $s 717744
BAS    __
$a 3
BMC    __
$a 2011 $b 5 $c 1 $d 15-24 $m Current Opinion in Critical Care (České vyd.) $x MED00156011
LZP    __
$a 2011-08/mkme

Najít záznam